Table 5 Tyrosine kinase inhibitors targeting the angiogenic pathway currently in clinical development in breast cancer

Sunitinib

VEGFR2, PDGFR-β, FLT3, c-Kit

Sorafenib

VEGFR1, 2 and 3, PDGFR-β, FLT3, c-Kit, Raf

Pazopanib

VEGFR1, 2 and 3, PDGFR-α/β, c-Kit

Vatalanib

VEGF1, 2 and 3, PDGFR, c-Kit, c-Fos

Cediranib

VEFGR1, 2 and 3, PDGFR, c-Kit

Vandetanib

VEGFR2, EGFR, RETS

AMG 706

VEGFR1, 2 and 3, PDGFR-β, c-kit

Axitinib

VEGFR1, 2 and 3, PDGFR, c-Kit